Table 3 Reported adverse events during the 4-week arginine vasopressin (AVP) treatment trial assessed by the DOTES and OAS scales.

Adverse events are reported as counts and percentages. Fisher’s exact test was used to test for differences in adverse events between the AVP and placebo treatment conditions. No significant effects were discerned. DOTES, Dosage Record Treatment Emergent Symptom Scale; OAS, Overt Aggression Scale; HEENT, head, ears, eyes, nose, and throat.

Adverse eventAVP (n = 17)Placebo (n = 13)
General
  Fever2 (12%)1 (8%)
  Cough1 (6%)0 (0%)
  Body ache1 (6%)0 (0%)
Neurological/
psychiatric
  Excitement/agitation4 (24%)1 (8%)
  Insomnia4 (24%)1 (8%)
  Increased motor
activity
4 (24%)0 (0%)
  Depressive affect2 (12%)1 (8%)
  Headache2 (12%)0 (0%)
  Drowsiness1 (6%)3 (23%)
  Decreased motor
activity
1 (6%)2 (15%)
  Aggression1 (6%)1 (8%)
  Akathisia1 (6%)0 (0%)
  Head banging1 (6%)0 (0%)
  Dizziness0 (0%)1 (8%)
  Lethargy/tiredness0 (0%)1 (8%)
HEENT
  Nasal congestion3 (18%)4 (31%)
  Dry mouth1 (6%)3 (23%)
  Blurred vision1 (6%)1 (8%)
  Ear infection0 (0%)1 (8%)
  Runny nose0 (0%)1 (8%)
  Sore throat0 (0%)1 (8%)
  Cold sore0 (0%)1 (8%)
Gastrointestinal
  Decreased appetite4 (24%)5 (38%)
  Nausea/vomiting2 (12%)2 (15%)
  Constipation1 (6%)0 (0%)
  Diarrhea0 (0%)1 (8%)
Renal
  Increased urination1 (6%)1 (8%)
  Bed-wetting1 (6%)0 (0%)
Dermatological
  Skin rash1 (6%)1 (8%)
  Bug bite1 (6%)0 (0%)
  Skin burn0 (0%)1 (8%)